New Drug may Offer Hope for Alzheimer's Patients

Karen Gatlin
Karen Gatlin
Contributor
Posted by Karen GatlinAugust 01, 2008 10:00 AM
Tags: None

The incidence of Alzheimer’s Disease is growing as the population of the United States is aging. A new drug, Rember, may slow or even halt the effects of Alzheimer’s Disease, a disease which affects millions of Americans and their caregivers. The diagnosis of Alzheimer’s Disease strikes fear in the hearts of patients because it not only affects daily functioning, but robs patients of their memories, of their thoughts, of their very selves. Drugs presently in use treat the symptoms of the disease, but not the cause. Rember destroys the protein which attacks the brains of Alzheimer patients by causing tangles in the nerve cells of the brain. Rember can dissolve the tangles.

Methylene blue, which has been used for years to treat chronic bladder infections, is one of the main chemicals in Rember. The drug is not yet available and must undergo further testing and development before it may be available for use. Researchers are very hopeful that Rember will significantly improve the lives of millions of patients who suffer from the disease.

0 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

Comments for this article are closed.

Subscribe to InjuryBoard Bergen County

InjuryBoard Bergen County RSS Feeds

Keep up with the latest updates using your favorite RSS reader

Legal Assistance Center

More Info
Better Business Bureau Accredited Business Confidential

Your question will be referred to an attorney near you. If your question is of a legal nature, then by submitting this form you agree you are not forming a formal attorney / client relationship. Read our full privacy policy.

Looking for an InjuryBoard attorney closer to home? Click here.

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address